Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Cancer Biol Ther
2016 Aug 02;178:824-32. doi: 10.1080/15384047.2016.1195046.
Show Gene links
Show Anatomy links
Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer.
Liang B
,
Zheng W
,
Fang L
,
Wu L
,
Zhou F
,
Yin X
,
Yu X
,
Zou Z
.
???displayArticle.abstract???
The targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a putative oncogene in different human cancers. This study assessed TPX2 expression in gastric cancer tissue samples and then determined the effects of TPX2 knockdown on the regulation of gastric cancer cell malignant behaviors in vitro. Tissue samples from 115 gastric cancer patients were analyzed for TPX2 expression. The effects of TPX2 siRNA on gastric cancer cells were assessed in vitro, including cell viability, cell cycle distribution, apoptosis, migration, and invasion. The data showed that TPX2 was overexpressed in gastric cancer tissues compared to that in the adjacent normal epithelia. Moreover, TPX2 overexpression was associated with a poor overall survival and was an independent prognostic predictor of gastric cancer. In addition, the in vitro study further confirmed the ex vivo data, i.e., knockdown of TPX2 expression reduced gastric cancer cell viability but induced apoptosis and arrested cells at the G2/M phase of the cell cycle. Knockdown of TPX2 expression also inhibited the tumor cell migration and invasion capacity in vitro. At the gene level, knockdown of TPX2 expression upregulated the levels of cyclin B1, cdk4, p53, Bax, caspase-3, and E-cadherin, but downregulated the levels of cyclin D1, cdk2, N-cadherin, slug, matrix metalloprotease (MMP)-2, and MMP-9, suggesting that knockdown of TPX2 expression suppressed tumor cell epithelial-mesenchymal transition (EMT). This study demonstrated that detection of TPX2 overexpression could serve as a prognostic marker and therapeutic target for gastric cancer.
Andl,
Targeting HCC Therapy: On or Off ToPiX?
2015, Pubmed
Andl,
Targeting HCC Therapy: On or Off ToPiX?
2015,
Pubmed
Asteriti,
The Aurora-A/TPX2 complex: a novel oncogenic holoenzyme?
2010,
Pubmed
Beroukhim,
The landscape of somatic copy-number alteration across human cancers.
2010,
Pubmed
Bogachek,
Regulation of epithelial-mesenchymal transition through SUMOylation of transcription factors.
2015,
Pubmed
Chambers,
Dissemination and growth of cancer cells in metastatic sites.
2002,
Pubmed
Chang,
The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer.
2012,
Pubmed
Cho,
Molecular diagnosis for personalized target therapy in gastric cancer.
2013,
Pubmed
Cunningham,
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
2006,
Pubmed
Cunningham,
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
2010,
Pubmed
Deryugina,
Matrix metalloproteinases and tumor metastasis.
2006,
Pubmed
Durães,
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?
2014,
Pubmed
Flucke,
Differences between biopsy- or specimen-related Laurén and World Health Organization classification in gastric cancer.
2002,
Pubmed
Grabsch,
Gastric cancer pathology and underlying molecular mechanisms.
2013,
Pubmed
Hsu,
TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma.
2014,
Pubmed
Kessenbrock,
Matrix metalloproteinases: regulators of the tumor microenvironment.
2010,
Pubmed
Kufer,
Human TPX2 is required for targeting Aurora-A kinase to the spindle.
2002,
Pubmed
,
Xenbase
Liang,
TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT.
2015,
Pubmed
Ma,
Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer.
2006,
Pubmed
Macdonald,
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
2001,
Pubmed
Neumayer,
TPX2: of spindle assembly, DNA damage response, and cancer.
2014,
Pubmed
Pérez de Castro,
A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy.
2007,
Pubmed
Pérez de Castro,
Mitotic Stress and Chromosomal Instability in Cancer: The Case for TPX2.
2012,
Pubmed
Ramakrishna,
Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis.
2010,
Pubmed
Scotto,
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression.
2008,
Pubmed
Sieber,
Genomic stability and tumorigenesis.
2005,
Pubmed
Smith,
20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome.
2006,
Pubmed
Smyth,
Targeted therapy for gastric cancer.
2012,
Pubmed
Tonon,
High-resolution genomic profiles of human lung cancer.
2005,
Pubmed
Van Cutsem,
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
2006,
Pubmed
Warner,
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.
2009,
Pubmed
Wei,
TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer.
2013,
Pubmed
Yan,
Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma.
2013,
Pubmed
Zhang,
Assignment of human proliferation associated p100 gene (C20orf1) to human chromosome band 20q11.2 by in situ hybridization.
1999,
Pubmed
